(1S,3S)-CPP-115 GABA-AT Inactivation for Safer Epilepsy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Long-term use of vigabatrin for treating epilepsy and addiction is limited by its side effect of causing visual field defects, which leads to restricted usage and safety concerns, necessitating a more effective and safer GABA aminotransferase inhibitor.
Innovation Solution
Development of (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid, a mechanism-based inactivator of GABA-AT, which is more potent than vigabatrin and does not inhibit GABA uptake or bind to GABA receptors, reducing the risk of visual field defects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vigabatrin is used to treat epilepsy and addiction, then GABA aminotransferase inhibition is achieved, but visual field defects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of vigabatrin to create compound 2, which has altered pharmacokinetic and pharmacodynamic properties. This structural modification results in an enzyme inactivator that is 186 times more potent than vigabatrin, allowing for significantly lower dosing and reduced visual field defects while maintaining therapeutic efficacy
Solution Approach 2:
The patent extracts and eliminates the harmful side effects of vigabatrin by developing a new compound that selectively inhibits GABA-AT without affecting GABA uptake or binding to GABA receptors. This extraction of the therapeutic mechanism from the harmful effects resolves the contradiction between efficacy and safety
2Reliability
If vigabatrin is used at high doses to achieve sufficient enzyme inhibition, then therapeutic effect is improved, but visual field defects worsen
Solution Approach 1:
The patent changes the potency parameter of the enzyme inactivator by 186-fold through structural modification, creating compound 2. This parameter change allows achieving the same therapeutic effect at much lower doses, thereby reducing the incidence and severity of visual field defects
Solution Approach 2:
The patent implements partial action by using significantly lower doses of the new compound compared to vigabatrin. The excessive potency of compound 2 means that only a small fraction of the dose required for vigabatrin is needed to achieve equivalent enzyme inhibition and therapeutic effect
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively blocks cocaine-induced dopamine increases and conditioned place preference at significantly lower doses than vigabatrin, with reduced risk of visual field defects, making it a safer alternative for treating epilepsy and addiction.
Implementation Method 1
The literature has shown that (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid is approximately 186 times more potent as a mechanism-based inactivator of γ-aminobutyric acid aminotransferase (GABA-AT) than the anticonvulsant drug and GABA-AT inactivator vigabatrin
Data Source
AI summary
(1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid also known as CPP-115 or its pharmaceutically acceptable salts can be used to treat addiction and neurological disorders such as epilepsy without side effects such as visual field defects caused by vigabatrin (Sabril).